HLA-DQB1 REFLECTS AN ANTIGEN-PRESENTATION-ASSOCIATED IMMUNE MICROENVIRONMENT IN BLADDER CANCER AND SHOWS RESPONSE-RELATED SIGNALS IN AN ATEZOLIZUMAB-TREATED COHORT
Bladder cancer is a heterogeneous malignancy with variable immune infiltration and limited response rates to immune checkpoint blockade. HLA-DQB1, a major histocompatibility complex class II gene involved in antigen presentation, may participate in tumor immune regulation. However, its expression pattern, prognostic relevance, immune microenvironmental associations, and immunotherapy-related significance in bladder cancer remain incompletely characterized. Transcriptomic and clinical data of bladder cancer were obtained from TCGA-BLCA. HLA-DQB1 expression was compared between tumor and normal tissues, and its association with overall survival was evaluated using Kaplan–Meier and Cox regression analyses. Single-sample gene set enrichment analysis was used to estimate immune-cell infiltration. Correlations between HLA-DQB1 and immune checkpoints, antigen-presentation genes, and immune-related modules were assessed using Spearman correlation analysis. Differential expression analysis between HLA-DQB1-high and HLA-DQB1-low tumors was performed using limma, followed by GO and Hallmark GSEA. External validation was conducted using GSE13507. Immunotherapy-related analyses were further performed in the IMvigor210 atezolizumab-treated urothelial carcinoma cohort. Public single-cell visualization was used as exploratory evidence of HLA-DQB1 cellular heterogeneity. In TCGA-BLCA, HLA-DQB1 expression did not differ significantly between tumor and normal tissues and was not significantly associated with overall survival. However, HLA-DQB1 showed strong positive associations with multiple immune-cell infiltration scores, including CD8 T cells, Tfh cells, macrophages, Th1 cells, NK cells, T cells, and Treg cells. HLA-DQB1 was also strongly correlated with antigen-presentation genes and immune-related markers, including HLA-DRA, HLA-DPA1, CD74, CIITA, PDCD1, CTLA4, HAVCR2, CXCL9, and CXCL10. GSEA revealed enrichment of immune activation, antigen presentation, interferon response, and inflammatory pathways in the HLA-DQB1-high group. In GSE13507, although tumor tissues showed lower HLA-DQB1 expression than normal bladder mucosa, the immune associations of HLA-DQB1 were externally reproduced. HLA-DQB1 was significantly correlated with antigen-presentation, myeloid/APC, T-cell-inflamed, and checkpoint-exhaustion module scores in both TCGA-BLCA and GSE13507. In the IMvigor210 cohort, HLA-DQB1 expression tended to be higher in responders, and after adjustment for tumor mutational burden, higher HLA-DQB1 expression was significantly associated with increased odds of response to atezolizumab. HLA-DQB1 expression showed cohort-dependent tumor-versus-normal patterns and was not significantly associated with overall survival in TCGA-BLCA. Across independent transcriptomic cohorts, HLA-DQB1 was consistently associated with MHC-II antigen-presentation-related and immune-inflamed transcriptional programs. Exploratory analysis of an atezolizumab-treated urothelial carcinoma cohort suggested an association with treatment response after adjustment for tumor mutational burden, although this finding requires further validation. Overall, HLA-DQB1 appears to reflect a broader immune-related transcriptional state rather than a validated independent prognostic or immunotherapy response biomarker.
Authors
- Zhongyi Qin (ORCID: https://orcid.org/0009-0002-5410-6073)
- JiaQiang Pan
- FangMing Xu
Institutions
- Guilin Medical University (CN)
Publication Details
- Journal
- Eurasia Journal of Science and Technology
- Published
- 2026-11-13
- DOI
- https://doi.org/10.61784/ejst3172
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00